BMC Cancer

Table 1 Baseline characteristics of CHOP and RCHOP patients before and after age, treatment intensity and propensity score matching

From: Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

		Before matching				After matching
Characteristics		CHOP	RCHOP	Std. diff	*P value*	CHOP	RCHOP	Std. diff	*P value*
		N = 1,196	N =2,825			N = 1,099	N = 1,099
Age at diagnosis
	Mean ± SD	56 · 7 ± 16	65 · 5 ± 14	0 · 62	<·001	57 · 5 ± 16	58 · 6 ± 15	0 · 07	0 · 12
Age group
	0-19	1%	<1%	0 · 09	<·001	<1%	<1%	0 · 00	1 · 00
	20-59	56%	25%	0 · 67		53%	53%	0 · 00
	60-69	19%	30%	0 · 25		20%	20%	0 · 00
	70-79	20%	33%	0 · 30		21%	21%	0 · 00
	80+	5%	12%	0 · 22		6%	6%	0 · 00
Female		47%	48%	0 · 01	0 · 74	47%	48%	0 · 00	0 · 93
ACG group
	0	<1%	<1%	0 · 09	<·001	<1%	<1%	0 · 00	0 · 96
	1-3	7%	5%	0 · 10		7%	7%	0 · 02
	4-6	24%	17%	0 · 18		23%	23%	0 · 00
	7-9	28%	31%	0 · 05		29%	31%	0 · 03
	10 +	40%	47%	0 · 16		41%	40%	0 · 02
Income quintile
	1	16%	17%	0 · 02	0 · 18	16%	15%	0 · 04	0 · 62
	2	20%	21%	0 · 02		19%	20%	0 · 02
	3	20%	19%	0 · 02		21%	21%	0
	4	24%	21%	0 · 08		23%	24%	0
	5	20%	22%	0 · 06		20%	20%	0 · 01
	Missing	<1%	<1%	0 · 02		<1%	<1%	0 · 07
Severity of disease
	Low	32%	30%	0 · 04	0 · 04	31%	31%	0 · 00	>0 · 99
	High	54%	58%	0 · 08		56%	56%	0 · 00
	Unclassifiable	15%	12%	0 · 07		13%	13%	0 · 00
Histology code
	9590	16%	20%	0 · 11	<·001	16%	16%	0 · 01	0 · 92
	9591	3%	3%	0 · 02		3%	2%	0 · 03
	9640	80%	69%	0 · 25		79%	80%	0 · 02
	9680	2%	9%	0 · 29		2%	2%	0 · 00
Median Follow-up time (years)		9 · 7	3 · 7			9 · 7	3 · 5

Std Diff, standardized difference; ACG, adjusted clinical group; Severity of disease was estimated using treatment intensity; Histology codes based on International Classification of Disease diagnosis codes.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com